Transthyretin Amyloidosis and the Kidney
Open Access
- 1 August 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 7 (8), 1337-1346
- https://doi.org/10.2215/cjn.08720811
Abstract
The amyloidoses are protein-misfolding disorders associated with progressive organ dysfunction. Immunoglobulin light chain is the most common, amyloid A the longest recognized, and transthyretin-associated amyloidosis (ATTR) the most frequent inherited systemic form. Although ATTR, an autosomal-dominant disease, is associated with at least 100 different transthyretin (TTR) mutations, the single amino-acid substitution of methionine for valine at position 30 is the most common mutation. Each variant has a different organ involvement, although clinical differences attributed to environmental and genetic factors exist within the same mutation. Peripheral neuropathy and cardiomyopathy are broadly described, and insights into disease reveal that kidney impairment and proteinuria are also clinical features. This review combines clinical and laboratory findings of renal involvement from the main geographic regions of disease occurrence and for different mutations of TTR. Fifteen nephropathic variants have been described, but the TTR V30M mutation is the best documented. Nephropathy affects patients with late-onset neuropathy, low penetrance in the family, and cardiac dysrhythmias. Microalbuminuria can be the disorder’s first presentation, even before the onset of neuropathy. Amyloid renal deposits commonly occur, even in the absence of urinary abnormalities. The experience with renal replacement therapy is based on hemodialysis, which is associated with poor survival. Because TTR is synthesized mainly in the liver, liver transplantation has been considered an acceptable treatment; simultaneous liver-kidney transplantation is recommended to avoid recurrence of nephropathy. In addition, the kidney-safety profile of new drugs in development may soon be available.Keywords
This publication has 73 references indexed in Scilit:
- Epigallocatechin-3-Gallate as a Potential Therapeutic Drug for TTR-Related Amyloidosis: “In Vivo” Evidence from FAP Mice ModelsPLOS ONE, 2012
- Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial PresentationCase Reports in Neurology, 2011
- Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosisJournal of Molecular Medicine, 2010
- Antibodies to human serum amyloid P component eliminate visceral amyloid depositsNature, 2010
- A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriersBMC Medical Genetics, 2010
- TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?European Journal of Human Genetics, 2010
- Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30MetJournal of the Neurological Sciences, 2009
- Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen Aα-Chain AmyloidosisJournal of the American Society of Nephrology, 2009
- Cardiac Amyloid in Patients with Familial Amyloid Polyneuropathy Consists of Abundant Wild-Type TransthyretinBiochemical and Biophysical Research Communications, 2000
- Localization of the human prealbumin gene to chromosome 18Biochemical and Biophysical Research Communications, 1985